Document:

Exhibit 10.10

                                 LOAN AGREEMENT

This Loan Agreement ("Agreement") is made and entered into effective as of the
30th day of January, 2002 by and between SurgiLight, Inc., a Delaware
corporation whose address is 12001 Science Drive, Suite 140, Orlando, FL 32826
("Company"), and Colette Cozean, Ph.D. an individual whose address is 21581
Midcrest Dr., Lake Forest, Ca 92630 ("Lender"). Collectively the "Parties".

                                 R E C I T A L S
                                 - - - - - - - -

WHEREAS, the Company desires to secure a second loan ("Loan") from the Lender to
make necessary payments according to payable commitments and agrees to the terms
and conditions set forth below;

WHEREAS, the Lender agrees to provide the loan to the Company;

          NOW, THEREFORE, the parties hereby agree as follows:

1. LOAN AMOUNT AND SECURITY
   ------------------------

The Company hereby desires to secure a loan from the Lender in the amount of
$20,000. The Company agrees to secure the loan the following collateral:
Intangible Assets ("Intangible Assets"), including, but not limited to, patents,
assigned patents, patent licenses and patents pending as set forth in Schedule
A.

2. INTEREST RATE
   -------------

The Company also agrees to pay 6% simple interest or the amount of interest
actually incurred by the Lender, whichever is greater to the Lender on the Loan.

3. WARRANTIES
   ----------

The Loan of $20,000 plus said interest shall be repaid prior to the Company
making payments for other obligations, except payroll and taxes, unless the
Company is released of this obligation in writing by Lender. The Company
warrants that the secured assets used as collateral for this Loan are free and
clear of any liens or encumbrances and may be used for said collateral. The
Company also warrants that the Patents listed are duly assigned or licensed to
the Company for the field of Ophthalmology. Additionally a form UCC-1 has been
signed on the date as set forth above.

The Lender acknowledges that this loan is granted on the same terms as a loan on
the date hereof from Dr. Stuart Michelson. Both notes have the same priority and
will be paid proportionately as funds become available.

<PAGE>

4. RELEASE OF SECURITY
   -------------------

Lender agrees to provide the loan in the amount of $20,000 and agrees to return
the ownership of the Patents as set forth in Schedule A when the $20,000 Loan,
the second loan and interest thereto is paid in full.

5. TERM
   ----

The term of this Agreement shall commence as of the effective date set forth
above and shall continue until the Loan of $20,000 plus said interest is
completely paid, whereupon the Agreement shall terminate, unless terminated
sooner in accordance herewith.

6. DEFAULTS
   --------

The Company will be in default of this Loan in the event of (i) bankruptcy, (ii)
the Company making payments, other than that for obtaining debt financing,
payroll or taxes, for other obligations before the Loan of $20,000 plus said
interest is repaid unless the Company is released of this obligation in writing
by Lender, and (iii) failure of the Company to repay the Loan in the amount of
$20,000 plus said interest within 60 days.

7. GENERAL
   -------

     a. All notices, requests, demands and other communications required or
permitted to be given under the terms of this Agreement shall be in writing and
shall be deemed to have been duly given if delivered personally, given by
facsimile, or mailed first class, postage prepaid or by registered or certified
mail.

     b. The Lender shall have no claim under this Agreement or otherwise against
the Company relating to the Loan for any employee benefits or withholding
obligations, all of which shall be the sole responsibility of Lender. The
Parties further agree that nothing in this Agreement creates the relationship of
partnership, joint venture, sales agency or principal and agent.

     c. The terms and provisions of this Agreement shall be binding on the
Lender, and shall inure to the benefit of the heirs, legal representatives,
successors and assigns of the Company. This Agreement is not assignable or
transferable and any attempt of such assignment, in whole or in part, shall be
null and void.

     d. This Agreement, including the Schedule(s) attached hereto, contains the
entire understanding and agreement of the Parties with respect to this loan, and
there are no representations, warranties, promises or undertakings other than
those contained in this Agreement. This Agreement does not supersede, affect nor
cancel any previous agreements, rights or obligations between the parties. No
course of conduct or dealing between the parties shall act as a modification or
waiver of any provision of this Agreement, and only a modification or waiver
which is contained in a written agreement, signed by both parties, shall be
effective.

                                       2

<PAGE>

     e. This Agreement shall be governed and construed in accordance with the
laws of the State of Florida, U.S.A., and the parties agree that it is executed
and delivered in that state.

     f. The Lender and the Company agree that all disputes arising out of or
concerning the terms of this Agreement will be subject solely to binding
arbitration. The arbitrator selection and conduct of the arbitration will be
pursuant to the Commercial Arbitration Rules of the American Arbitration
Association. The place of the arbitration shall be in Orange County, Florida and
judgment on the award may be entered in any court having jurisdiction thereof.
If either party believes it is necessary to undertake discovery on asserted
statutory claims, such party shall apply to the arbitrator or arbitrators for
rights to undertake discovery, and the arbitrator shall allow discovery
sufficient for either party to adequately arbitrate, vindicate, or defend the
statutory claims, including access to essential documents and witnesses. At the
conclusion of the arbitration, the arbitrator or arbitrators shall issue a
decision in writing setting forth the essential findings and conclusions, and
this decision is subject to review, confirmation, correction, or vacation
pursuant to the provisions Code of Civil Procedure 1285 through 1288.8 in effect
at the time the decision is rendered.

     g. If any provision of this Agreement should be held to be void or
unenforceable, in whole or in part, such provision or part thereof shall be
treated as severable, leaving valid the remainder of this Agreement.

IN WITNESS WHEREOF, the parties have executed this Agreement as of the date
first set forth above.

DATED:   _______________                    LENDER:

                                            By:  ____________________________
                                                  Colette Cozean, Ph.D.

DATED:   ________________                   SURGILIGHT, INC

                                            By:  ____________________________
                                                  Timothy J. Shea
                                                  Senior Vice President
                                                  Chief Operating Officer

                                       3

<PAGE>
<TABLE>
<CAPTION>

                                                               PATENTS
                                                               -------
                                                              SCHEDULE A
                                                              ----------

                                                              EXHIBIT A1
                                                              ----------
                                                           LICENSED PATENTS

--------------------- ------------------------------------------ ------------- -------------- ---------- ------------- -------------
<S>                   <C>                                        <C>           <C>            <C>        <C>           <C>
Case Number           Title of Invention                         Country       Appl. No.      Filing     Patent No.    Issue Date
                                                                                              Date
--------------------- ------------------------------------------ ------------- -------------- ---------- ------------- -------------

PREMLS.001FW1*        MEDICAL LASER INTERCONNECT SYSTEM          USA           07/568,549     8/16/90    5,116,329     5/26/92
--------------------- ------------------------------------------ ------------- -------------- ---------- ------------- -------------

PREMLS.001VCA*                            "                      CANADA        2,000,916      10/18/89   2,000,916     1/17/95
--------------------- ------------------------------------------ ------------- -------------- ---------- ------------- -------------

PREMLS.001VEP*                            "                      EUROPE        89310520.5     10/13/89   0365228       12/14/94
--------------------- ------------------------------------------ ------------- -------------- ---------- ------------- -------------

PREMLS.001VJP*                            "                      JAPAN         282,818/89     10/30/89   3,084,029     6/30/00
--------------------- ------------------------------------------ ------------- -------------- ---------- ------------- -------------

PREMLS.002FW1*        FIBER OPTIC APPARATUS FOR USE WITH         USA           07/803,919     12/6/91    5,207,673     5/4/93
                      MEDICAL LASERS
--------------------- ------------------------------------------ ------------- -------------- ---------- ------------- -------------

PREMLS.002VAU*                            "                      AUSTRALIA     56,921/90      6/7/90     613,560       12/11/91
--------------------- ------------------------------------------ ------------- -------------- ---------- ------------- -------------

PREMLS.002VCA*                            "                      CANADA        2,018,450      6/7/90     2,018,450     5/9/95
--------------------- ------------------------------------------ ------------- -------------- ---------- ------------- -------------

PREMLS.009DV1*        LASER SURGICAL PROBE                       USA           08/841,865     5/5/97
--------------------- ------------------------------------------ ------------- -------------- ---------- ------------- -------------

PREMLS.009FW4*        TRANSPARENT LASER SURGICAL PROBE           USA           08/419,511     4/7/95     5,688,261     11/18/97
--------------------- ------------------------------------------ ------------- -------------- ---------- ------------- -------------

PREMLS.009QCA*                            "                      CANADA        2,107,687      4/3/92
--------------------- ------------------------------------------ ------------- -------------- ---------- ------------- -------------

PREMLS.009QEP*                            "                      EUROPE        92910340.6     4/3/92     0578756       8/30/000
--------------------- ------------------------------------------ ------------- -------------- ---------- ------------- -------------

PREMLS.011DV1*        CONTACT TIP FOR LASER SURGERY              USA           08/455,061     5/31/95    6,110,167     8/29/00
--------------------- ------------------------------------------ ------------- -------------- ---------- ------------- -------------

PREMLS.011FW4*                            "                      USA           08/457,992     6/1/95     5,707,368     1/13/98
--------------------- ------------------------------------------ ------------- -------------- ---------- ------------- -------------

PREMLS.018DV1*        MULTIWAVELENGTH MEDICAL LASER METHOD       USA           07/917,589     7/17/92    5,304,167     4/19/94
--------------------- ------------------------------------------ ------------- -------------- ---------- ------------- -------------

*previously licensed to SurgiLight for Erbium Ophthalmic field of use

                                                               - A1 -
</TABLE>

<PAGE>
<TABLE>
<CAPTION>

--------------------- ------------------------------------------ ------------- -------------- ---------- ------------- -------------
<S>                   <C>                                        <C>           <C>            <C>        <C>           <C>
Case Number           Title of Invention                         Country       Appl. No.      Filing     Patent No.    Issue Date
                                                                                              Date
--------------------- ------------------------------------------ ------------- -------------- ---------- ------------- -------------

PREMLS.018FW2         MULTIWAVELENGTH MEDICAL LASER SYSTEM       USA           07/754,327     9/4/91     5,139,494     8/18/92
--------------------- ------------------------------------------ ------------- -------------- ---------- ------------- -------------

PREMLS.018VAU                             "                      AUSTRALIA     44,520/89      11/9/89    626,339       2/1/93
--------------------- ------------------------------------------ ------------- -------------- ---------- ------------- -------------

PREMLS.018VCA                             "                      CANADA        2,002,453      11/8/89    2,002,453     1/17/95
--------------------- ------------------------------------------ ------------- -------------- ---------- ------------- -------------

PREMLS.018FW4         METHOD OF LASER SURGERY USING MULTIPLE     USA           08/422,648     4/14/95    5,540,676     7/30/96
                      WAVELENGTHS
--------------------- ------------------------------------------ ------------- -------------- ---------- ------------- -------------

PREMLS.050A*           HIGH REPETITION RATE MID-INFRARED LASER   USA           08/240,255     5/10/94    5,422,899     6/6/95
--------------------- ------------------------------------------ ------------- -------------- ---------- ------------- -------------

PREMLS.050VAU*                            "                      AUSTRALIA     17,964/95      5/9/95     688,593       5/7/98
--------------------- ------------------------------------------ ------------- -------------- ---------- ------------- -------------

PREMLS.050VCA*                            "                      CANADA        2,148,395      5/2/95
--------------------- ------------------------------------------ ------------- -------------- ---------- ------------- -------------

PREMLS.050VEP*                            "                      EUROPE        95302891.7     4/28/95    0682389       9/2/98
--------------------- ------------------------------------------ ------------- -------------- ---------- ------------- -------------

PREMLS.050VKR*                            "                      KOREA         11,234/1995    5/9/95
--------------------- ------------------------------------------ ------------- -------------- ---------- ------------- -------------

PREMLS.050VIL*        HIGH PULSE REPETITION AND ITS USE          ISRAEL        113,501        4/26/95    113,501       5/19/97
--------------------- ------------------------------------------ ------------- -------------- ---------- ------------- -------------

PREMLS.050VJP*        PULSED, OPTICALLY PUMPED LASER AND         JAPAN         110,517/1995   5/9/95
                      SURGICAL METHOD USING THE SAME
--------------------- ------------------------------------------ ------------- -------------- ---------- ------------- -------------
                                          "
PREMLS.050DV2*                                                   USA           08/931,600     9/17/97    6,122,300     9/19/00
--------------------- ------------------------------------------ ------------- -------------- ---------- ------------- -------------

PREMLS.081A*          SINGLE DOMINANT SPIKE OUTPUT ERBIUM LASER  USA           09/360,588     7/26/99
--------------------- ------------------------------------------ ------------- -------------- ---------- ------------- -------------

PREMLS.081VPC*                            "                      WO            PCTUS00/20241  7/26/00
--------------------- ------------------------------------------ ------------- -------------- ---------- ------------- -------------

PREMLS.112A           OPTICAL SOURCE AND METHOD                  USA           09/303,697     5/3/99
--------------------- ------------------------------------------ ------------- -------------- ---------- ------------- -------------

PREMLS.112VAU                             "                      AUSTRALIA     46981/00       5/3/00
--------------------- ------------------------------------------ ------------- -------------- ---------- ------------- -------------

PREMLS.112VCA                             "                      CANADA                       5/3/00
--------------------- ------------------------------------------ ------------- -------------- ---------- ------------- -------------

PREMLS.112VEP                             "                      EUROPE        00928801.0     5/3/00
--------------------- ------------------------------------------ ------------- -------------- ---------- ------------- -------------

PREMLS.112VJP                             "                      JAPAN                        5/3/00
--------------------- ------------------------------------------ ------------- -------------- ---------- ------------- -------------

*previously licensed to SurgiLight for Erbium Ophthalmic field of use

                                                               - A2 -
</TABLE>

<PAGE>
<TABLE>
<CAPTION>

                                                             EXHIBIT A2
                                                             ----------

                                                         NEW ASSIGNED PATENT

--------------------- ------------------------------------------ ------------- -------------- ---------- ------------- -------------
<S>                  <C>                                         <C>           <C>            <C>        <C>           <C>

Case Number           Title of Invention                         Country       Appl. No.      Filing     Patent No.    Issue Date
                                                                                              Date
--------------------- ------------------------------------------ ------------- -------------- ---------- ------------- -------------

PREMLS.055FW3         LASER SURGICAL METHOD USING TRANSPARENT    USA           08/391,612     2/21/95    5,722,970     3/3/98
                      PROBE
--------------------- ------------------------------------------ ------------- -------------- ---------- ------------- -------------

                                                               - B1 -
</TABLE>

<PAGE>

                                    INVENTORY
                                    SCHEDULE B

                              SCHEDULE A -- Page 1Exhibit 10.11

            Manufacturing and Marketing License and Royalty Agreement

This Manufacturing and Marketing and Royalty Agreement (this "Agreement") is
entered into by and between RA Medical Systems, Inc., a California corporation
("RA") and Surgilight, Inc., a Florida corporation ("SRGL"), effective as of
______________, 2003.

A. SRGL has received clearances from the US Food and Drug Administration
("FDA"), denominated 510K k993328 and k020973, to market a laser device having
certain specifications, ("Specifications"). The FDA clearances referred to the
device as EX-308. SRGL desires to license to RA exclusive manufacturing rights
and exclusive marketing rights for this device, including any derivative
devices, substantially conforming to the specifications as well as the exclusive
right to use its mark EX-308 on devices RA intends to manufacture and market.

B. In consideration of the foregoing, RA is willing to pay SRGL certain
royalties on its Gross EX-308 Revenues during the royalty term as set forth
herein. NOW THEREFORE, the parties agree as follows:

1. CERTAIN DEFINITIONS.

   (a) "Manufacturing Rights" means the exclusive and unencumbered right to
       manufacture.

   (b) "Marketing Rights" means the exclusive and unencumbered right to promote
       and sell.

   (c) "EX-308 Excimer Laser" is the name applied to any product cleared to
       market by the FDA under 510k k993328 and k020973 and bearing the mark
       "EX-308".

   (d) "Specifications" includes a list of parameters measuring performance,
       physical and other properties of the EX-308, including complete copies of
       the 510k submissions of the EX-308 Excimer Laser. These specifications
       may also include any drawings, charts, and tables sufficient to
       understand the performance and characteristics of the EX-308 Excimer
       Laser, but in no case shall SRGL be required to generate drawings or
       other materials to facilitate the transfer to RA

   (e) "Gross EX-308 Revenues" means one hundred percent (100%) of all amounts
       accrued by RA, its subsidiaries and its affiliates, as revenues, under
       generally accepted accounting principles consistently applied, from the
       sale or lease of a EX-308 Excimer Laser, but shall not include any
       amounts received for sales, use or other transaction taxes, duties or

   (f) "Royalty Term" means the twelve (12) consecutive calendar quarters,
       commencing with the first calendar quarter after the date of this
       Agreement in which RA has operating revenues from commercial
       subscriptions, advertising sales and/or consumer product royalties or, at
       the election of SRGL, any calendar quarter prior thereto.

Transfer and Royalty Agreement           1                   Initials __________

<PAGE>

      (g) "RA Products" means products designed and manufactured by RA. If an RA
          product does not bear the mark EX-308 and is not represented as having
          been cleared under FDA 510k k993328 or k020973, sales of such RA
          product will not be included in gross EX-308 Revenues regardless of
          whether it was manufactured according to the specifications.

      (h) "Aggregate Royalties" shall mean the total of all royalties paid by RA
          to SRGL until the termination of this Agreement.

2. TRANSFER. In consideration of the agreement to pay royalties by RA as set
forth in Section 3 below, SRGL transfers to RA exclusive Manufacturing and
exclusive Marketing Rights in and to the EX-308 Excimer Laser. The
Specifications will be delivered to RA within ten (10) days of the execution of
this Agreement.

3. PAYMENT OF ROYALTIES. In consideration of the transfer made by SRGL pursuant
to the provision of Section 2 above, RA hereby agrees to pay to SRGL royalties
equal to three percent (3%) of RA's Gross EX-308 Revenues for each calendar
quarter during the Royalty Term, up to the aggregate amount of thirty seven
thousand five hundred ($37,500) dollars, after this amount has been reached, RA
agrees to pay to SRGL royalties equal to one-half percent (0.5%) of RA's Gross
EX-308 Revenues for each remaining calendar quarter during the Royalty Term. RA
shall make the payments due to SRGL hereunder with respect to Gross EX-308
Revenues for each of the calendar quarters during the Royalty Term not later
than sixty (60) days after the end of such calendar quarter. RA will not pay
royalties on any RA Products not bearing the EX-308 mark. RA intends to develop
laser devices having specifications substantially identical to the
Specifications which will have separate and distinct FDA clearances. RA will
notify SRGL when RA intends to conclude manufacturing and marketing of the
EX-308. On that date, RA shall return the rights to manufacture and market under
510k k993328 and k020973 to SRGL and the Agreement shall be terminated according
to Section 5.

4. AUDITED FINANCIALS, RECORDKEEPING AND INSPECTION. RA hereby agrees to provide
to SRGL unaudited financial statements for each calendar quarter in the Royalty
Term within thirty (30) days following the end of such calendar quarter. RA
hereby agrees to provide to SRGL, upon request, financial statements audited by
an accounting firm for each calendar in the Royalty Term within ninety (90) days
following the end of such calendar year. If the Gross Revenues reported on such
audited financial statements differ from the cumulative amounts shown on the
quarterly reports for such calendar year, an adjustment payment shall be made by
the party benefiting from the error to correct the error within twenty (20) days
following delivery of the applicable audited financial statement. RA shall keep
at its usual place or places of business complete records of its Gross Revenues
for each calendar quarter, for a period of not less than three (3) years
following the end of such calendar quarter, and will regularly make entries in
such records at its earliest business convenience for the purpose of showing the
amounts payable to SRGL hereunder. On not less than ten (10) days written
notice, SRGL shall have the right, not more than once during any twelve (12)
month period at mutually agreed upon times

Transfer and Royalty Agreement         2                    Initials __________

<PAGE>

during normal business hours at SRGL's expense, to examine any and all of RA's
records reflecting Gross Revenues for the sole purpose of verifying the accuracy
of RA's reports of Gross Revenues and the performance of RA's obligations to
make payments hereunder. In the event that any such examination by SRGL
discloses an error in the determination of any amounts due hereunder that is
confirmed by RA's independent auditors, an adjustment payment shall be made by
the party which benefited from the error to correct the error within twenty (20)
days following such independent auditor's confirmation of the error. In the
event that any such examination by SRGL discloses an error in the determination
of any amounts due hereunder, that is confirmed by RA's independent auditors,
such that amount previously paid to SRGL was too low, SRGL shall be entitled to
8% on any unpaid amounts and SRGL thereafter shall be entitled to examine RA's
books and records on a quarterly basis.

5. TERMINATION. This Agreement shall terminate at the end of the Royalty Term or
earlier pursuant to notification from RA under Section 3, or if no royalty
payment has been made to SRGL by RA for two consecutive quarters. Upon
termination, RA shall immediately pay to SRGL the $37,500 minus the Aggregate
Royalty. If the Aggregate Royalty exceeds $37,500, RA shall pay nothing to SRGL.

6. DISPUTE RESOLUTION. SRGL and RA agree that all disputes arising out of or
concerning the terms of this Agreement will be subject solely to binding
arbitration. The arbitrator selection and conduct of the arbitration will be
pursuant to the Commercial Arbitration Rules of the American Arbitration
Association. The place of the arbitration shall be in Orange County, California
and judgment on the award may be entered in any court having jurisdiction
thereof. If either party believes it is necessary to undertake discovery on
asserted statutory claims, such party shall apply to the arbitrator or
arbitrators for rights to undertake discovery, and the arbitrator shall allow
discovery sufficient for either party to adequately arbitrate, vindicate, or
defend the statutory claims, including access to essential documents and
witnesses. At the conclusion of the arbitration, the arbitrator or arbitrators
shall issue a decision in writing setting forth the essential findings and
conclusions, and this decision is subject to review, confirmation, correction,
or vacation pursuant to the provisions Code of Civil Procedure 1285 through
1288.8 in effect at the time the decision is rendered.

7. CONTROLLING LAW. This Agreement is entered into and to be performed in
California, and it shall be interpreted and enforced under, and all questions
relating thereto shall be determined in accordance with the laws of the State of
California.

8. WAIVER. No waiver of any provision of this Agreement shall be deemed or shall
constitute a waiver of any other provision, whether or not similar, nor shall
any waiver constitute a continuing waiver. No waiver shall be binding unless
executed in writing by the party making the waiver.

Transfer and Royalty Agreement          3                    Initials __________

<PAGE>

9. PARTIAL INVALIDITY. The illegality, invalidity or unenforceability of any
provision of this Agreement under the law of any jurisdiction shall not affect
its legality, validity or enforceability under the law of any other jurisdiction
nor the legality, validity or enforceability of any other provision.

10. ENTIRE AGREEMENT. This Agreement is intended by the parties as a final
expression of their agreement and as a complete and exclusive statement of the
terms of their agreement with respect to its subject matter. This Agreement may
not be contradicted by evidence of any prior or contemporaneous agreement, oral
or written, and this Agreement may not be explained or supplemented by evidence
of consistent additional terms. This Agreement supersedes, merges, and voids all
prior representations, statements, negotiations, understandings, proposed
agreements, and other agreements, written or oral, relating to its subject
matter.

11. AMENDMENTS. This Agreement may not be amended, modified or supplemented
except by a writing executed by both parties.

12. COUNTERPARTS. This Agreement may be signed in counterparts, each an original
but all one and the same instrument.

13. SUCCESSORS AND ASSIGNS. This Agreement shall inure to the benefit of the
successors and assigns of SRGL and any successors and permitted assigns of RA,
and shall be binding upon the successors and assigns of SRGL and of RA.

14. FURTHER ASSURANCES. The parties hereto shall do and perform or cause to be
done and performed all such further acts and things and shall execute and
deliver all such other documents as any other party may reasonably request from
time to time in order to carry out the intent and purpose of this Agreement
contemplated hereby. Neither SRGL nor RA shall voluntarily undertake any course
of action inconsistent with satisfaction of the requirements applicable to them
set forth in this Agreement and each shall promptly do all such acts and take
all such measures as may be appropriate to enable them to perform as early as
practicable the obligations herein required to be performed by them.

15. NOTICES. Any notice or other communication required or permitted under this
Agreement shall be in writing and either personally delivered or deposited in
the first class United States mail, prepaid, certified or registered, return
receipt requested, addressed as follows:

Transfer and Royalty Agreement        4                      Initials __________

<PAGE>

(a)       If to SRGL:

            Surgilight, Inc.
            12001 Science Dr. Ste. 140
            Orlando, Florida 32826
            Attn:  President

(b) If to RA:

            RA Medical Systems, Inc.
            7040 Avenida Encinas, #104-256
            Carlsbad, California 92009
            Attn:  President

Notice shall be deemed to have been given upon receipt. Either party may change
its address by giving written notice of such change to the other party in the
manner provided in this Section.

IN WITNESS WHEREOF, the parties have executed this Agreement effective as of the
date first above written.

RA Medical Systems, Inc.                    Surgilight, Inc.

By: _______________________                 By: ______________________

Title:                                      Title:

Transfer and Royalty Agreement        5                      Initials __________

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00052-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00052-of-00352.parquet"}]]